MHH nationwide leader in blood cancer therapy

We are searching data for your request:

Forums and discussions:
Manuals and reference books:
Data from registers:
Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.

MHH doctors nationwide leading in therapy for blood cancer

Radiation or chemotherapy is used as a treatment for both and diseases. These procedures are generally known as agents against tumors and cancer. If blood cancer cannot be successfully treated with this, the only way to cure patients is a blood stem cell transplant. If the donor is the same person, speaks of a so-called “. Donors and recipients are often different people. The experts then speak of an "allogeneic" blood stem cell transplant. Most patients receiving this therapy have some form of acute leukemia.

The Hannover Medical School (MHH) for hematology, hemostaseology, oncology and stem cell transplantation is the nationwide leader in allogeneic stem cell transplantation. Under the direction of Professor Dr. Arnold Ganser can cure 62 percent of all adult patients suffering from acute melodic leukemia (AML), a malignant disease of the hematopoietic system. The national average is only 50 percent. AML is characterized by the fact that cancer cells in the bone marrow and blood prevent normal blood formation.

MHH is the most successful nationwide. 52 percent of MHH patients are also healthy again with other types of blood cancer, such as myelodysplastic syndrome (MDS) and myeloproliferative neoplasia (MPN). Here, too, the national average is 40 percent. MDS is a disease of the bone marrow which causes a disturbance in blood formation and which can then become an AML. MPN, on the other hand, are blood disorders that arise as a result of cancerous stem cells. Doctors only consider patients cured if there are no relapses in the disease five years after the transplant and there have been no transplant consequences.

Stem cell transplantation register enables comparisons Opportunities to compare individual centers with one another only emerged with the introduction of the German stem cell transplantation register (DRST). All patients who had had blood stem cells transplanted from 1998 to 2012 are registered in this. “The results show the extraordinarily good quality of the allogeneic stem cell transplantation at the MHH for the diagnoses AML and MDS / MPN. The first registration is a confirmation that we are on the right path and that we do not have to shy away from comparison with other centers. Such an evaluation also helps patients decide where they want to be transplanted, ”says Professor Ganser.

For the first time, thanks to the register, data on the Germany-wide average could be determined and the responsible persons informed that many patients had actually exceeded the five-year limit after a transplant and could therefore be classified as cured. According to the database, allogeneic stem cell transplants were carried out in 45 centers in Germany in 2012 in more than 3,100 adults. 2,900 received a transplant for the first time. Looking at the development, it can be seen that there has been a steady increase in AML and MDS transplants for ten years. (fr)

Image: Dieter Schütz /

Author and source information

Video: Acute myeloid u0026 lymphoblastic leukemia - causes, symptoms u0026 pathology


  1. Vita

    I agree, this excellent thought, by the way, falls

  2. Tojazuru

    more details please

  3. Bemeere

    Granted, that will have a good idea just by the way

  4. Alvino

    Bravo, science fiction))))

  5. Shaktiktilar

    Thanks for the miracle))

Write a message

Previous Article

Breast cancer through hormone treatments

Next Article

Increases norovirus diseases in Lower Saxony